Pune, Jan. 11, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Neuropathic Pain Therapeutics Market By Drug Class (Antidepressants, Anticonvulsants, Local Anesthesia, Opioids, and Steroids), By Application (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-induced Peripheral Neuropathy, Trigeminal Neuralgia, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) - Global Outlook & Forecast 2022-2030" published by Growth Plus Reports, the Neuropathic Pain Therapeutics Market is expected to grow at a CAGR of 4.9% from 2021 to reach US$ 9.22 billion by 2030.
Download PDF Brochure of Neuropathic Pain Therapeutics Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at:
https://www.growthplusreports.com/inquiry/request-sample/neuropathic-pain-therapeutics-market/8006
Growth Drivers
Although there are other signs of neuropathic pain, diabetic neuropathy is the most typical one. According to the CDC, diabetic neuropathy is anticipated in 60–70% of diabetes patients. The market for neuropathic pain management will expand as a result of the rise in neuropathic pain incidences caused by the growing population of diabetic patients.
The global neuropathic pain therapeutics market has been analyzed from three perspectives: drug, application, distribution channel, and region.
Excerpts from ‘By Drug Class Segmentation’
Based on drug class, the global neuropathic pain therapeutics market is subdivided into:
- Antidepressants
- Anticonvulsants
- Local Anesthesia
- Opioids
- Steroids
It has been analyzed that the opioid segment dominates the neuropathy pain drugs market. This is because of the high number of prescriptions of opioid drugs by the practitioners. Though, use of antidepressants for the treatment of neuropathic pain has been increasing and would be increasing in the upcoming years.
Excerpts from ‘By Region Segmentation’
Based on region, the global neuropathic pain therapeutics market has been segmented into:
- North America
- Europe
- Asia Pacific
- The Rest Of The World
In the forecast period, Asia Pacific region is expected to grow with a high CAGR. The market for neuropathic pain drugs is anticipated to rise as a result of rising R&D spending by different industry participants to develop cutting-edge goods. Growing older populations and a high risk of neuropathic pain in many nations will open opportunities for the market for neuropathic pain to expand. The presence of various key players in the market is also one of the factors driving the market in this region.
Excerpts from ‘Competitive Landscape’
The prominent players operating in the global neuropathic pain therapeutics market are:
- Pfizer Inc.
- Iqure Pharma
- Janssen Pharmaceuticals, Inc.
- Novartis Ag
- Glaxosmithkline
- Eli Lilly And Company
- Astrazeneca
- Bayer Ag
- Abbvie
- Algiax Pharmaceuticals Gmbh
- Haisco Pharmaceutical Group Co., Ltd.
- Aptinyx
- Biogen
- Alzecure Pharma
- Shanghai Simr Biotechnology Co., Ltd.
- Lexicon Pharmaceuticals
Browse Detailed Summary of Research Report with TOC:
https://www.growthplusreports.com/report/neuropathic-pain-therapeutics-market/8006
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2020
- Base Year – 2021
- Forecasted Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
- Antidepressants
- Anticonvulsants
- Local Anaesthesia
- Opioids
- Steroids
- Others
- GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY APPLICATION
- Diabetic Neuropathy
- Spinal Stenosis
- Chemotherapy-induced Peripheral Neuropathy
- Trigeminal Neuralgia
- Others
Scope of the Report:
| Report Attribute | Details |
| Market size value in 2021 | US$ 6 billion |
| Revenue forecast in 2030 | US$ 9.22 billion |
| Growth Rate | CAGR of 4.9% from 2022 to 2030 |
| Base year for estimation | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | drug class, application, distribution channel, and region |
| Regional scope | North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pipeline Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Directly Purchase Premium Copy of Neuropathic Pain Therapeutics Market Growth Report (2022-2030) at:
About Us
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
